Peer-Reviewed Publication
Redox Rep2026;31(1):2626151.December 1, 2026Journal Article
XFM and HERFD-XAS studies of selenium in tissues and whole blood from mice supplemented with potentially therapeutic selenocompounds.
Ani T Baker1, Tamara Ortiz-Cerda2,3, Kangzhe Xie3, Jordan Hunter3, Iliya Dragutinovic4, Jonathan C Morris4, Linda I Vogt5, Graham N George5, Dimosthenis Sokaras6, Daryl L Howard7, Paul K Witting3, Hugh H Harris1
1Discipline of Chemistry, The University of Adelaide, Adelaide, Australia.
2Departamento de Citología e Histología Normal y Patológica, Facultad de medicina, Universidad de Sevilla, Seville, Spain.
3Redox Biology Group, Charles Perkins Centre, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
4School of Chemistry, Faculty of Science, Kensington, UNSW Sydney, NSW, Sydney, Australia.
5Department of Geological Sciences, University of Saskatchewan, Saskatoon, Canada.
6Stanford Synchrotron Radiation Lightsource, SLAC National Accelerator Laboratory, Menlo Park, CA, USA.
7Australian Synchrotron, ANSTO, Clayton, Australia.
Abstract
BACKGROUND: Selenium nanoparticles (SeNPs) and selenoneine (SeN) are prospective nutritional supplements and therapeutic agents postulated to counteract Se deficiency and alleviate oxidative stress induced by various pathological conditions.
METHODS: X-ray fluorescence microscopy (XFM) and high energy resolution fluorescence detected X-ray absorption spectroscopy (HERFD-XAS) investigated Se distr…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans